Cargando…
Expression of Concern: Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites
Expression of Concern for ‘Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites’ by Maorong Wang et al., RSC Adv., 2020, 10, 8044–8053, https://doi.org/10.1039/C9RA10593J.
Autores principales: | Wang, Maorong, Yao, Ping, Gao, Minpeng, Jin, Jian, Yu, Yerong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679917/ https://www.ncbi.nlm.nih.gov/pubmed/36425214 http://dx.doi.org/10.1039/d2ra90118h |
Ejemplares similares
-
Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites
por: Wang, Maorong, et al.
Publicado: (2020) -
Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects
por: Zhong, Xia, et al.
Publicado: (2019) -
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
por: Zhang, Hongkai, et al.
Publicado: (2015) -
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020) -
A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)